
Aprea Therapeutics Cash $41.2M; Runway into Q1 2028
Aprea Therapeutics reported a net loss of $3.59 million for Q2 2026, an increase from $3.24 million in Q2 2025. However, the company significantly strengthened its financial position, with cash and cash equivalents rising to $41.2 million by June 30, 2026, up from $14.6 million at year-end 2025. This increase was primarily due to successful private placements, extending its cash runway into the first quarter of 2028. Diluted net loss per share improved to $(0.07) from $(0.53) due to a substantial increase in shares outstanding.
Key Highlights
- Cash and cash equivalents increased to $41.2 million as of June 30, 2026.
- Cash runway extended into Q1 2028, providing crucial liquidity.
- Net loss for Q2 2026 was $3.59 million, up from $3.24 million in Q2 2025.
- Diluted net loss per share improved to $(0.07) from $(0.53) in Q2 2025.
- Net cash provided by financing activities totaled $32.7 million for H1 2026.
- Weighted-average common shares outstanding rose to 53.5 million in Q2 2026.
- Research and development expenses for Q2 2026 were $2.46 million.
Price Impact
More from APRE
Aprea Therapeutics Reports Positive Interim Data for APR-1051 Trial
Aprea Therapeutics Q3 Net Loss Widens to $4.81M; Cash Funds Operations into 2028
Aprea Therapeutics Reports Q3 2026 Results; Cash Runway to Q1 2028